Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Trial Profile

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Delayed graft function
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2014 Results presented at the World Transplant Congress 2014.
    • 01 Jul 2014 According to the Quark Pharmaceuticals media release, results from this trial will be presented at the World Transplant Congress 2014 on 26 - 31 Jul 2014.
    • 01 Jul 2014 Status changed from active, no longer recruiting to completed according to the Quark Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top